Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study
ConclusionConsistent with clinical trial findings, nearly 80% of patients who initiated SZC for HK optimized their RAASi therapy. Patients may require long-term SZC therapy to encourage continuation of RAASi therapy especially after inpatient and ED visits.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Chronic Kidney Disease | Clinical Trials | Databases & Libraries | Diabetes | Drugs & Pharmacology | Emergency Medicine | Endocrinology | Sodium | Study | Urology & Nephrology